Currently, some compounds for wasting disorders in chronic HF are being tested in preclinical and clinical settings [113]—acylated ghrelin has a potential anti-catabolic effect, as demonstrated by an experimental study conducted in a chronic HF rat model [114], possibly by regulation of the UPS rate-limiting E-3 ubiquitin ligases, muscle RING-finger protein-1 (MuRF-1) and Muscle Atrophy F-box (MAFbx)/atrogin-1 [115]. This evidence concerns the gene GHRL and hydrops fetalis.